152 related articles for article (PubMed ID: 32743472)
1. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.
Fujiwara M; Komai Y; Yuasa T; Numao N; Yamamoto S; Fukui I; Yonese J
IJU Case Rep; 2020 Mar; 3(2):62-64. PubMed ID: 32743472
[TBL] [Abstract][Full Text] [Related]
2. Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer.
Kageyama T; Soga N; Sekito S; Kato S; Ogura Y; Kojima T; Kanai M; Inoue T
IJU Case Rep; 2022 Nov; 5(6):442-445. PubMed ID: 36341181
[TBL] [Abstract][Full Text] [Related]
3. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.
Yoshida T; Yaegashi H; Toriumi R; Kadomoto S; Iwamoto H; Izumi K; Kadono Y; Ikeda H; Mizokami A
Front Oncol; 2022; 12():912490. PubMed ID: 36185251
[TBL] [Abstract][Full Text] [Related]
4. [Experience of Pembrolizumab Administration in A Patient with Castration-Resistant Microsatellite Instability-High Prostate Cancer].
Takasawa T; Amano T; Himeno M; Imao T
Hinyokika Kiyo; 2024 Feb; 70(2):51-54. PubMed ID: 38447945
[TBL] [Abstract][Full Text] [Related]
5. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
[TBL] [Abstract][Full Text] [Related]
6. Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series.
Ravindranathan D; Russler GA; Yantorni L; Drusbosky LM; Bilen MA
Case Rep Oncol; 2021; 14(1):190-196. PubMed ID: 33776702
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
[TBL] [Abstract][Full Text] [Related]
9. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
Reed-Perino DE; Lai M; Yu EY; Schweizer MT
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Tsai AK; Kagalwalla S; Langer J; Le-Kumar T; Le-Kumar V; Antonarakis ES
Expert Opin Biol Ther; 2024; 24(1-2):51-62. PubMed ID: 38284349
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS
Eur Urol; 2023 Jan; 83(1):15-26. PubMed ID: 36055895
[TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report.
Oshima M; Mayumi S; Yazaki K; Nakamura Y; Konishi T; Saito K; Washino S; Miyagawa T
IJU Case Rep; 2019 Jul; 2(4):179-182. PubMed ID: 32743405
[TBL] [Abstract][Full Text] [Related]
13. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report.
Hidaka Y; Arigami T; Osako Y; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jun; 20(1):193. PubMed ID: 35689267
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
[TBL] [Abstract][Full Text] [Related]
16. Durable response to pembrolizumab in microsatellite instability-high advanced adrenocortical carcinoma.
Senda M; Hashimoto K; Shindo T; Kobayashi K; Tanaka T; Masumori N
IJU Case Rep; 2023 Nov; 6(6):382-385. PubMed ID: 37928286
[TBL] [Abstract][Full Text] [Related]
17. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T; Uemura H; Sumitomo M; Harada K; Sugimoto M; Hayashi N; Yoshimura K; Fukasawa S; Ecstein-Fraisse E; Sunaga Y; Oya M
Jpn J Clin Oncol; 2019 Aug; 49(8):766-771. PubMed ID: 31329922
[TBL] [Abstract][Full Text] [Related]
18. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
19. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
20. ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Stein MN; Fong L; Tutrone R; Mega A; Lam ET; Parsi M; Vangala S; Gutierrez AA; Haas NB
Oncologist; 2022 Jun; 27(6):453-461. PubMed ID: 35373299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
